preview

 

Wednesday, 18 January, 2017
All Day Exhibit Setup
10:00 – 19:00 Registration Open
10:00 – 19:00 Poster Setup
18:00 – 19:00 Welcome and Opening Remarks
Joseph Jankovic (USA)
Alberto Albanese (Italy)
Lifetime Achievement Award Ceremony
Recipient: Mark Hallett (USA)
19:00 – 19:30 Dasgupta Memorial Lecture
Cesare Montecucco (Italy)
19:30 – 22:00 Welcome Reception
Thursday, 19 January, 2017
07:00 – 18:30 Registration/Information
07:00 – 08:30 Exhibits
Plenary Session
08:30 – 08:40 Welcome and Opening Remarks and Introduction of Keynote Speaker
Andreas Rummel (Germany)
08:40 – 09:30 Keynote Presentation – Presynaptic Functions
Erik M. Jorgensen (USA)
09:30 – 10:00 Assembly and Disassembly of the SNARE Complex
Axel Brunger (USA)
10:00 – 10:30 What’s the Best Dosage and Interval for BoNT Injections in Dystonia and Spasticity Treatment?
Jorg Wissel (Germany)
10:30 – 11:00 Break
11:00 – 11:30 Recent Developments in Clinical Trials of BoNT
Alberto Albanese (Italy)
11:30 – Noon Advances in the Architecture of the BoNT Complex
Rongsheng Jin (USA)
12:00 – 13:30 Lunch
12:00 – 14:30 Exhibits
12:00 – 13:30 Lunchtime Satellite Symposium
Supported by an unrestricted educational grant from MERZ.
12:00 – 14:30 Poster Session
Participants will break into separate groups for Basic Science, Clinical, Workshops A, and Workshops B.
Parallel Track I (Basic Science)
14:30 – 18:30 Genetics and Evolution
Chair: Cesare Montecucco (Italy)
14:30 – 15:00 Regulation of C. Botulinum Growth and Toxin Production
Miia Lindström (Finland)
15:00 – 15:30 Botulinum Neurotoxin Homologs in Non-Clostridial Species
Andrew Doxey (Canada)
15:30 – 16:00 Two Selected Abstracts
16:00 – 16:30 Break
16:30 – 18:30 Molecular Interactions I
Chair: Giampietro Schiavo (UK)
16:30 – 17:00 Binding of BoNT to Gycosylated SV2
Stefan Mahrhold (Germany)
17:00 – 17:30 Botulinum Neurotoxin Type A Enters a Non-Recycling Pool of Synaptic Vesicles
Fredric Meunier (Australia)
17:30 – 18:00 Models of Drug-Induced Epileptiform Synchronization in Vitro: How Does Epileptic Activity Spread?
Jordi Molgo (UK)
18:00 – 18:30 Translocation and Dissemination to Target Neurons of Botulinum Neurotoxin Type B in the Mouse Intestinal Wall
Michael Popoff (France)
18:30 – 20:00 INA Business Meeting
20:00 – 22:30 Faculty Dinner
Clinical Tracks 1A & 1B
14:30 – 16:00 Oromandibular Dystonia
Chair: Cindy Comella (USA)
14:30 – 15:00 Pathophysiology and Clinical Features
Ryuji Kaji (Japan)
15:00 – 15:30 Systematic Review of BoNT Treatment
Cindy Comella (USA)
15:30 – 16:00 Practical Tips for BoNT Treatment
16:00 – 16:30 Break
16:30 – 18:00 Urological Use of BoNT
Chair: TBD
16:30 – 17:00 Overactive Bladder Management Strategy and Role of BoNT
17:00 – 17:30 Emerging Applications of BoNT to Treat Pelvic Pain Syndromes
Christopher Smith (USA)
17:30 – 18:00 Update on BoNT Injections in Multiple Sclerosis and
Interstitial Cystitis/Bladder Pain Syndrome Patients

Francisco Cruz (Portugal)
Clinical Tracks 2A & 2B
14:30 – 16:00 Lifespan Management of Muscle Activity in Cerebral Palsy (CP)
Chair: Katharine Alter (USA)
14:30 – 15:00 Management of Pediatric Cerebral Palsy
Florian Heinen (Germany)
15:00 – 15:30 Management of Adolescents/Teens
15:30 – 16:00 Transition and Management of Adults
Cindy Ivanhoe (USA)
Clinical Workshops 1A & 1B
14:30 – 18:00 Cosmetic Uses I
Chair: Jean Carruthers (Canada)
14:30 – 15:00 Introduction to the Anatomy of Facial Aesthetics
Jonathan Sykes (USA)
15:00 – 15:30 Evidence-Based Review of BoNT Injections for Aesthetic Use
15:30 – 16:00 BoNT Injections for Glabellar Frown Lines and Crow’s Feet Lines
Jean Carruthers (Canada)
16:00 – 16:30 Break
16:30 – 18:00 Cosmetic Uses Injection Workshop with Live Patients
Master Injector: Juan Sopena (Spain)
Clinical Workshops 2A & 2B
14:30 – 18:00 Hand Dystonia
Chair: Mark Hallett (USA)
14:30 – 15:00 Pathophysiology and Therapy Other Than BoNT
Kirsten Zeuner (Germany)
15:00 – 15:30 Review of Clinical Trials
Condrin Lungu (USA)
15:30 – 16:00 Muscle Selection for BoNT
16:00 – 16:30 Break
16:30 – 18:00 Hand Dystonia Injection Workshop
with Live Patients

Clinical Workshops 3A & 3B
14:30 – 18:00 Hemifacial Spasm and Blepharospasm
Chair: Raymond Rosales (Philippines)
14:30 – 15:00 Applying Tailored Assessment Scales in BoNT Injections
15:00 – 15:30 A Review of Evidence of BoNT Treatment
Raymond Rosales (Philippines)
15:30 – 16:00 Practical Tips for BoNT Treatment
16:00 – 16:30 Break
16:30 – 18:00 Hemifacial Spasm and Blepharospasm Injection Workshop with Live Patients
Master Injector: Francisco Grandas (Spain)
Clinical Workshops 4A & 4B
14:30 – 18:00 Cervical Dystonia
Chair: Buz Jinazz (USA)
14:30 – 15:00 Review of Long-Term Studies and Registries
Buz Jinazz (USA)
15:00 – 15:30 What are the Obstacles to Optimal Patient Outcomes?
15:30 – 16:00 Strategies to Increase Patient-Perceived Benefit
Joseph Tsui, (Canada)
16:00 – 16:30 Break
16:30 – 18:00 Cervical Dystonia Injection Workshop
with Live Patients

Friday, 20 January, 2017
Plenary Session
08:30 – 09:00 Evidence on BoNT in Selected Disorders
David Simpson (USA)
09:00 – 09:30 The Booming Number of Novel Botulinum Neurotoxins: A Pandora’s Box of Novel Properties
Eric Johnson (USA)
09:30 – 10:00 Potential New Uses of BoNT Injections in Movement Disorders
Joseph Jankovic (USA)
10:00 – 10:30 Break
10:30 – 11:00 The Binding of BoNT to Different Peripheral Neurons
Ornella Rossetto (Italy)
11:00 – 11:30 Central Effects of BoNT
Matteo Caleo (Italy)
11:30 – Noon BoNT for Pain Syndromes
Bahman Jabbari (USA)
Parallel Track I (Basic Science)
14:30 – 18:30 Molecular Interaction II
Chair: Mauricio Montal (USA)
14:30 – 15:00 Botulinum Toxin A Complex Exploits Intestinal M Cells to Enter the Host and Exert Neurotoxicity
Yukako Fujinaga (Japan)
15:00 – 15:30 Two Selected Abstracts
15:30 – 16:00 Two Selected Abstracts
16:00 – 16:30 Break
16:30 – 18:30 Novel BoNTs and Toxin Engineering
Chair: Sabine Pellett (USA)
16:30 – 17:00 Structural and Functional Insights Into the Interaction of BoNT/A Light Chain With SNAP-25 and SNAP-23
Thomas Binz (Germany)
17:00 – 17:30 Two Selected Abstracts
17:30 – 18:00 Non-Paralytic BoNTs for Pain Control
Bazbek Davletov (UK)
18:00 – 18:30 Targeted Delivery of a SNARE Protease to Sensory Neurons Using a Single Chain Antibody (scFv) Against the Extracellular Domain of P2X(3) Inhibits the Release of a Pain Mediator
Richard O’Kennedy (Ireland)
Clinical Tracks 1A & 1B
14:30 – 16:00 Spasmodic Dysphonia
Chair: Andrew Blitzer (USA)
14:30 – 15:00 Pathology and Treatment Effects in Spasmodic Dysphonia
15:00 – 15:30 Long-Term Experience With BoNT for Spasmodic Dysphonia
Andrew Blitzer (USA)
15:30 – 16:00 Research Priorities in Spasmodic Dysphonia
16:00 – 16:30 Break
16:30 – 18:00 Other Neurological Uses
Chair: Francisco Cardoso (Brazil)
16:30 – 17:00 BoNT in Parkinsonism: The When, How, and Which for BoNT Injections
Francisco Cardoso (Brazil)
17:00 – 17:30 Tremors: The When, How, and Which for BoNT Injections
17:30 – 18:00 Tics: The When, How, and Which for BoNT Injections
Peter Moore (UK)
Clinical Workshops 1A & 1B
14:30 – 16:00 Headache and Facial Pain
Chair: TBD
14:30 – 15:00 Who Benefits Most? Predictors of Treatment Response
15:00 – 15:30 Can Treatment be Stopped Successfully in “Super Responders”?
15:30 – 16:00 Technical Aspects of the Use of BoNT for Treatment of Chronic Migraine
16:00 – 16:30 Break
16:30 – 18:00 Headache and Facial Pain Injection Workshop
with Live Patients

Clinical Workshops 2A & 2B
14:30 – 18:00 Cosmetic and Dermatologic Uses II
Chair: Ellen Gendler (USA)
14:30 – 15:00 Aesthetic BoNT Injections of the Face: Options and Outcomes
Ellen Gendler (USA)
15:00 – 15:30 BoNT Injections for Hyperhidrosis: Technical Pearls
Dee Anna Glaser (USA)
15:30 – 16:00 Hyperhidrosis: Sympathectomy or BoNT Injections?
16:00 – 16:30 Break
16:30 – 18:00 Cosmetic and Dermatologic Uses II Injection Workshop with Live Patients
Master Injector: Juan Sopena (Spain)
Clinical Workshop 3A & 3B
14:30 – 18:00 Spasticity
Chair: TBD
14:30 – 15:00 Pathophysiology, Assessment, and Goal Setting in Treatment of Spasticity
15:00 – 15:30 Botulinum Toxin in the Treatment of Upper Extremity Spasticity
15:30 – 16:00 Botulinum Toxin in the Treatment of Lower Extremity Spasticity
Alberto Esquenazi (USA)
16:00 – 16:30 Break
16:30 – 18:00 Spasticity Injection Workshop
with Live Patients

Clinical Workshops 4A & 4B
14:30 – 18:00 Techniques for Localizing Muscles for BoNT Injections
Chair: Marina de Koning-Tijssen (Amsterdam)
14:30 – 15:00 EMG/Electrical Stimulation
Marina de Koning-Tijssen (Amsterdam)
15:00 – 15:30 Ultrasound
Katharine Alter (USA)
15:30 – 16:00 Other Techniques
Erle Lim (Singapore)
16:00 – 16:30 Break
16:30 – 18:00 Lifespan Management of Muscle Activity in Cerebral Palsy Injection Workshop with Live Patients
Master Injector: Ignacio Pascual Pascual (Spain)
Saturday, January 21, 2017
General Session
08:30 – 8:45 Poster Awards
08:45 – 09:00 Poster Awards
09:00 – 9:20 Controversy – PRO
BoNT for Headache:
PREEMPT vs. Individualized Treatment
09:20 – 09:40 Controversy – CON
BoNT for Headache:
PREEMPT vs. Individualized Treatment
09:40 – 10:20 TeNT Uptake and Transport
Giampietro Schiavo (UK)
10:20 – 10:30 Closing Remarks
10:30 – 11:00 Break
Parallel Track I (Basic Science)
11:00 – 13:30 Basic Science Track Detection and Protection
Chair: Markus Kalkum (USA)
11:00 – 11:30 CMAP for Quantitative Detection of BoNTs
Yasushi Torii (Japan)
11:30 – Noon Two Selected Abstracts
Noon – 12:30 Endopep-MS and Hc-Based Neutralizing Oligoclonal Antibody Mixture
12:30 – 13:00 Outcome of the ANTIBOTABE mAB Development Project
Michael Hust (Germany)
14:00 – 15:00 Incoming INA Board Meeting
19:00 – 22:00 Corporate Social Events

 

 

 

 

 

 

 

 

 

 

 

 


——- BELOW THIS LINE IS INTERNAL TEMPLATE. DISREGARD EVERYTHING BELOW ——-

Click here for the Lunchtime Symposia schedule.

Print this page.

——- BELOW THIS LINE IS PICKED UP FROM THE BOTTOM OF THE PREVIOUS LIVE PAGE.  ——-

 

Basic Science Sessions

Genetics and Evolution

  • Regulation of Clostridium botulinum Growth and Toxin Production
  • The Fecal Microbiota of Infants with Botulism
  • Two Selected Abstracts

Molecular Interactions I

  • Binding of BoNT to Glycosylated SV2
  • Botulinum Neurotoxin A Enters a Non-Recycling Pool of Synaptic Vesicles
  • Models of Drug-Induced Epileptiform Synchronization in Vitro/How Does Epileptic Activity Spread?
  • Mechanism of BoNTs in Targeting Pain Processing

Molecular Interactions II

  • Botulinum Toxin A Complex Exploits Intestinal M Cells to Enter the Host and Exert Neurotoxicity
  • Two Selected Abstracts
  • Two Selected Abstracts

Novel BoNTs and Toxin Engineering

  • Structural and Functional Insights into the Interaction of BoNT/A Light Chain with SNAP-25 and SNAP-23
  • Two Selected Abstracts
  • Non-Paralytic BoNTs for Pain Control
  • Engineering Botulinum Neurotoxin Domains for Activation by Toxin Light Chain

Detection of and Protection Against Botulinum Toxins

  • CMAP for Quantitative Detection of BoNTs
  • Two Selected Abstracts
  • Endopep-MS and HC-Based Neutralizing Oligoclonal Antibody Mixture
  • Outcome of the antiBotABE mAB Development Project

Clinical Sessions

Cervical Dystonia

  • Review of Long-Term Studies and Registries
  • What are the Obstacles to Optimal Patient Outcomes?
  • Strategies to Increase Patient-Perceived Benefit

Cosmetic and Dermatologic Use – I

  • Introduction to the Anatomy of Facial Aesthetics
  • Evidence-Based Review of BoNT Injections for Aesthetic Use
  • BoNT Injections for Glabellar Frown Lines and Crow’s Feet Lines

Cosmetic and Dermatologic Use – II

  • Aesthetic BoNT Injections of the Face: Options and Outcomes
  • BoNT Injections for Hyperhidrosis: Technical Pearls
  • Treatment of Hyperhidrosis: Sympathectomy or BoNT Injections?

Hand Dystonia

  • Pathophysiology and Therapy Other Than BoNT Injections
  • Review of Clinical Trials
  • Muscle Selection for BoNT Injections

Headache and Facial Pain

  • Who Benefits Most? Predictors of Treatment Response
  • Can Treatment be Stopped Successfully in ‘Super-Responders’?
  • Technical Aspects of the Use of BoNT for Treatment of Chronic Migraine

Hemifacial Spasm and Blepharospasm

  • Applying Tailored Assessment Scales in BoNT Injections
  • A Review of the Evidence for BoNT Treatment
  • Practical Tips for BoNT Treatment

Oromandibular Dystonia

  • Pathophysiology and Clinical Features
  • Systematic Review for BoNT Treatment
  • Practical Tips for BoNT Treatment

Other Neurological Uses

  • BoNT in Parkinsonism: The When, How, and Which for BoNT Injections
  • Tremors: The When, How, and Which for BoNT Injections
  • Tics: The When, How and Which for BoNT Injections

Spasmodic Dysphonia

  • Pathology and Treatment Effects in Spasmodic Dysphonia
  • Long Term-Experience With BoNT for Spasmodic Dysphonia
  • Research Priorities in Spasmodic Dysphonia

Spasticity

  • Pathophysiology, Assessment, and Goal Setting in Treatment of Spasticity
  • Botulinum Toxin in the Treatment of Upper Extremity Spasticity
  • Botulinum Toxin in the Treatment of Lower Extremity Spasticity

Cerebral Palsy

Techniques for Localizing Muscles for BoNT Injections

  • EMG/Electrical Stimulation
  • Ultrasound
  • Other Techniques

Urological Use of BoNT

  • Overactive Bladder Management Strategy and the Role of BoNT
  • Emerging Applications of BoNT to Treat Pelvic Pain Syndromes
  • Update on BoNT Injection in MS-Associated Bladder Dysfunction and Interstitial Cystitis/Bladder Pain Syndrome Patients

Workshops

  • Cervical Dystonia (Live Patient Injections)
  • Oromandibular/Craniofacial Laryngeal Dystonias (Live Patient Injections and Video Demonstrations)
  • Blepharospasm and Strabismus (Live Patient Injections and Video Demonstrations)
  • Focal Limb Dystonias (Live Patient Injections)
  • Spasticity (Live Patient Injections)
  • Headache/Migraine (Live Patient Injections)
  • Dermatology/Aesthetics (Live Patient Injections)
  • Urology (Video and Pelvic Model Demonstrations)
  • Gastroenterology (Video Demonstrations)